On Apr. 6, 2020, Biotest, BPL Group, LFB, and Octapharma joined an alliance formed by CSL Behring and Takeda Pharmaceutical to develop a potential plasma-derived therapy for treating COVID-19.

The alliance began with the investigational development of one, unbranded anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin medicine with the potential to treat individuals with serious complications from COVID-19.